Endoscopic Instrument Patents: Who Leads, Where the Gaps Are 2026
- 43.6% concentration. The top 5 of 55 ranked assignees hold 95 of 218 records in scope — nearly half the field sits with a handful of filers.
- Filing has cooled since 2019. Volume peaked at 12 records that year and has declined toward 1 in the most recent (partial) year, with the 2022 midpoint already back to 6.
- Claim space is narrow outside A61B. Every record in scope carries an A61B class; only optics (G02B, 6.4%) and fluid-handling (A61M, 6.9%) show meaningful secondary activity.
What this dataset covers
This landscape draws on 218 published records filed between 2015 and mid-2026 that combine endoscopic instrument or single-use/disposable endoscope terminology with claim language around cross-contamination risk, image quality versus cost trade-offs, articulation, sterilization avoidance, or environmental footprint, restricted to A61B1, H04N23 and A61B17 classifications. That combination targets the specific commercial tension in this field: reusable, high-image-quality endoscopic instruments carry sterilization and cross-contamination cost, while single-use designs trade some of that away for disposability and simpler compliance.
Because publication lags filing by roughly 18 months, the most recent year of the trend understates real activity; treat 2025 and 2026 figures as a floor, not a ceiling. Family counts, not raw document counts, are used throughout the ranking so that multi-jurisdiction filing by a single applicant does not inflate its apparent share.
Filing trend and technology composition
Two views of the same 218 records: how filing volume has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend, 2017–2026
Filings ran at 10 in 2017, rose to a peak of 12 in 2019, and had fallen back to 6 by the 2022 midpoint, continuing to decline toward 1 in the most recent (partial) year — a flat-to-declining pattern rather than a growth curve.
IPC subclass composition
Every record in scope carries an A61B classification (100.0% of 218), confirming the search scope. Beyond that base, secondary activity clusters in body-fluid devices (A61M, 6.9%) and optical systems (G02B, 6.4%), with implants (A61F, 1.8%), robotic manipulators (B25J, 1.4%) and sterilising equipment (A61L, 0.5%) each covering a narrow slice. Since a record can carry several classes, these shares sum to more than 100% of the 218-record base.
Shares are the percentage of the 218 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Endoscopic Instruments and Single-Use Endoscopes with Eureka
This page is one run against one query. Ask Eureka your own question about endoscopic instruments and single-use endoscopes and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
US8114017B2 — Articulating endoscopic instrument (Karl Storz, 2012-02-14)
An endoscopic instrument comprises a shaft with proximal and distal ends. A grip with a handle sits at the proximal end; a tool with open and closed positions sits at the distal end. The shaft has two sections, the second of which articulates relative to the first and carries the tool. An actuating element connects the handle to the second section and initiates articulation of that section.Abstract trimmed for length; see the full record for complete claim language.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5792165A | Endoscopic instrument with detachable end effector | 2,776 |
| 2 | US5330502A | Rotational endoscopic mechanism with jointed drive mechanism | 2,657 |
| 3 | US5405344A | Articulable socket joint assembly for an endoscopic instrument for surgical fastner track therefor | 2,224 |
| 4 | US5368015A | Automated surgical system and apparatus | 2,179 |
| 5 | US5501654A | Endoscopic instrument having articulating element | 2,173 |
| 6 | US5275608A | Generic endoscopic instrument | 2,053 |
| 7 | US8603135B2 | Articulating surgical apparatus | 1,422 |
| 8 | US8114017B2 | Articulating endoscopic instrument | 969 |
| 9 | EP0646356A2 | Articulable socket joint assembly for an endoscopic instrument and surgical fastener track therefor | 956 |
| 10 | US6019780A | Dual pin and groove pivot for micro-instrument | 628 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this corpus; read them as a signal of influence on subsequent drafting, not as a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three findings that should shape where a new filing targets claim space in this field.
The lead group has room, the middle does not
With 95 of 218 records held by the top 5 of 55 ranked assignees, and the leader alone holding 25, new entrants face dense prior art wherever those assignees have already claimed articulation and end-effector mechanics. The long tail below tenth place (7 records) suggests single-filing entrants still find room at the margins.
Filing has cooled, not accelerated
Volume peaked in 2019 and has declined through the 2022 midpoint of 6 toward a single record in the latest partial year. Several of the most active named assignees show zero filings in the latest year tracked, consistent with a maturing rather than expanding claim landscape.
Secondary claim space is thin
Beyond the universal A61B base, only fluid-handling (A61M) and optics (G02B) show more than a handful of records, at 6.9% and 6.4% of 218 respectively. Implants, robotic manipulation and sterilising equipment each sit under 2%, marking them as comparatively open branches rather than crowded ones.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to endoscopic instruments and single-use endoscopes, with the prior art for and against each one.
Who is filing, and where the gate sits
The ranking behind this page covers 55 companies, counted in families, not a top-50 or top-100 cut. It is worth reading the concentration numbers alongside the recent-year momentum, because several of the largest historical filers show no activity in the latest year tracked.
A single filer holds the largest single share
The leading assignee's 25 records sit well ahead of fifth place at 15, but even that leading share is a minority of the 218-record field — no single company controls the space outright.
A tight mid-tier, then a drop-off
Fifth place holds 15 records and tenth place holds 7 — roughly half the leading position's count. The top 10 combined account for 70.2% of all 218 records, leaving a long tail of smaller and single-filing entrants to split the remainder.
Co-filing is rare, not structural
Only four co-assignee pairs appear across the dataset, the strongest linking a major scope manufacturer with a named inventor on two records. This is a field of independent corporate filers rather than joint-venture or cross-licensed development.
| Assignee | Recent year | YoY |
|---|---|---|
| Ethicon Endo-Surgery, Inc. | 0 | — |
| Covidien LP | 0 | — |
| Interscope, Inc. | 0 | — |
| Intuitive Surgical Operations, Inc. | 0 | — |
| Richard Wolf GmbH | 0 | — |
| Boston Scientific Scimed, Inc. | 0 | — |
| Karl Storz SE & Co. KG | 0 | -100% |
| Gyrus Medical Ltd. | 0 | — |
Where to take this analysis
The figures on this page are a starting point for a freedom-to-operate check or a whitespace filing strategy, not a substitute for one.
Check claim scope against the leading assignees
Before drafting in articulation or end-effector mechanics, review the granted claims held by the top 5 ranked assignees, who together hold 43.6% of the 218 records in scope.
Explore assignee claims in EurekaTrace the most-cited prior art forward
The most-cited records in this set date back to the 1990s; use forward-citation mapping to see which recent filings build on them before assuming a mechanism is unclaimed.
Run a citation map in EurekaTest a claim against the under-claimed branches
Sterilisation-avoidance and robotic-assisted articulation both show thin IPC coverage relative to the A61B base — a targeted search will confirm whether that reflects genuine white space or under-indexing.
Search white space in EurekaCommon questions on this landscape
Across the 218 records in this dataset, filing is concentrated but not dominated by one company: the leading assignee holds 25 records, and the top 5 of 55 ranked assignees together hold 95 records, or 43.6% of the field. That leaves a majority of records spread across a long tail of smaller filers, including many with only one or two records each. Anyone assessing freedom to operate should check both the leading group's claims and the specific mechanism they are working on, since the tail filers often hold narrow but blocking claims in niche areas.
Not on the current trend. Filings peaked at 12 records in 2019, had fallen to 6 by the 2022 midpoint, and continued declining toward 1 in the most recent partial year tracked. Because publication typically lags filing by around 18 months, the last one to two years will likely revise upward as more records publish, but the multi-year direction through 2022 is clearly downward rather than accelerating. This pattern is more consistent with a maturing claim landscape than an expanding one.
This dataset does not separate reusable from single-use filings as distinct classes, but the search terms combine both, alongside cross-contamination risk, sterilization avoidance, image quality versus cost, articulation and environmental footprint language. All 218 records carry an A61B classification, with secondary activity concentrated in body-fluid handling (A61M, 6.9%) and optics (G02B, 6.4%). That secondary split is a reasonable proxy for where single-use-specific engineering claims tend to land, since fluid management and lower-cost optics are common trade-offs in disposable designs.
US8114017B2, assigned to Karl Storz and dated 2012-02-14, covers an endoscopic instrument with a shaft split into two sections, where the distal section carries the tool and articulates relative to the proximal section via an actuating element connected to the handle grip. Anyone designing an articulating endoscopic instrument with this handle-to-tool actuation architecture should review its specific claim language closely, since the mechanism described sits squarely in the most heavily cited technical territory in this dataset. Design-around approaches typically look at alternative actuation paths that do not route through a handle-connected actuating element in the same configuration.
The clearest under-claimed branches by IPC share are sterilising and disinfecting equipment (A61L, 0.5% of 218 records), robotic manipulators (B25J, 1.4%), and implant-compatible tooling (A61F, 1.8%) — all thin compared to the universal A61B base. That thinness does not guarantee the space is legally open; it may reflect under-indexing rather than a genuine gap, so a targeted freedom-to-operate search on the specific mechanism is still necessary. Combined with the flat-to-declining overall filing trend, these branches are worth investigating before assuming the core articulation and end-effector claims are the only viable filing target.
Research Endoscopic Instruments and Single-Use Endoscopes in depth with Eureka
Go past this page: query the whole endoscopic instruments and single-use endoscopes corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.